“Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma”, Mediterr J Hematol Infect Dis, vol. 17, no. 1, p. e2025051, Jun. 2025, doi: 10.4084/MJHID.2025.051.